Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             210 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 2.37 Accelerated Activity of the Mevalonate Pathway Supports the Immune Escape and Multidrug- Resistance Phenotype of IGHV Unmutated Chronic Lymphocytic Leukemia Cells Coscia, M.
 2011
 11 S2 p. S182-
1 p.
 artikel
2 5.48 Action of Novel Cd37 Antibodies on CLL Cells Krause, Günter
 2011
 11 S2 p. S277-
1 p.
 artikel
3 4.14 Activation-Induced Cytidine Deaminase Expression and Function in CLL is an Independent Risk Factor for Poor Patient Outcome Chu, Charles C.
 2011
 11 S2 p. S226-S227
2 p.
 artikel
4 2.17 Activation of STAT3 Increases Mitochondrial Respiration and Protects Mitochondria from Oxidative Damage in Chronic Lymphocytic Leukemia Jia, Li
 2011
 11 S2 p. S170-S171
2 p.
 artikel
5 5.54 Ad-ISF35 Transduced Autologous Cells Induce Chemosensitization Activity and Complete Responses in Fludarabine-Refractory and/or del(17p)/p53-Defective Chronic Lymphocytic Leukemia Patients Melo-Cardenas, Johanna
 2011
 11 S2 p. S281-S282
2 p.
 artikel
6 5.58 Advances in the Use of Targeted Nanoparticles for the Treatment of B-CLL Mansilla, E.
 2011
 11 S2 p. S284-
1 p.
 artikel
7 5.19 AMD3100 Disrupts Cross-talk Between Chronic Lymphocytic Leukemia Cells and Their Microenvironment: Preclinical Evidence for Its Association with CLL Treatments Stamatopoulos, Basile
 2011
 11 S2 p. S255-S256
2 p.
 artikel
8 4.17 A Novel Approach to Minimal Residual Disease Assessment in Chronic Lymphocytic Leukaemia Utilizing the Tumour Specific Antigen CD160 Farren, Timothy
 2011
 11 S2 p. S228-S229
2 p.
 artikel
9 2.6 Anti-Inflammatory Curcumin Inhibits Activation-Induced Cytosine Deaminase (AID) within Cycling Normal and CLL B Lymphocytes Haque, Shabirul
 2011
 11 S2 p. S163-
1 p.
 artikel
10 4.4 ARSD Is a New Biomarker Associated with IgVH, ZAP-70, and Disease Progression in CLL Trojani, Alessandra
 2011
 11 S2 p. S219-S220
2 p.
 artikel
11 2.21 Autocrine Interleukin-6 Production Correlated with Survival of Chronic Lymphocytic Leukaemia Cells Liu, Fengting
 2011
 11 S2 p. S172-
1 p.
 artikel
12 2.39 B-Cell Chronic Lymphocytic Leukemia Mesenchymal Stromal Cells: Implications for the Survival and Bone Marrow Localization of a Leukemic Clone Ave, E.
 2011
 11 S2 p. S183-S184
2 p.
 artikel
13 1.6 BCR Stimulation in CLL, Regardless of Mutation Status, Increases Expression of miR-132 and miR-212 Pede, Valerie
 2011
 11 S2 p. S144-S145
2 p.
 artikel
14 5.9 Bendamustine and Alemtuzumab Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia: Interim Report of the Italian Trial Tedeschi, A.
 2011
 11 S2 p. S247-S248
2 p.
 artikel
15 5.5 Bendamustine and Lenalidomide in Relapsed/Refractory CLL Ujjani, Chaitra S.
 2011
 11 S2 p. S245-
1 p.
 artikel
16 3.4 Benefits and Limits of 18F-Fluoro-Deoxyglucose Positron Emission Tomography/Computed Tomography in Patients with CLL and Small Lymphocytic Lymphoma Papajik, Tomas
 2011
 11 S2 p. S198-S199
2 p.
 artikel
17 2.25 BH3 Profiling Demonstrates that CAL-101 Restores Apoptotic Priming in Stroma-Exposed Chronic Lymphocytic Leukemia Cells Davids, Matthew S.
 2011
 11 S2 p. S174-S175
2 p.
 artikel
18 5.35 Btk Inhibitor, PCI-32765, Delays CLL Progression in a TCL1 Adoptive Transfer Model by Impairing Migration and Cell Proliferation Chen, Shih-Shih
 2011
 11 S2 p. S266-S267
2 p.
 artikel
19 1.30 Caspase 10 is Down-Regulated in Chronic Lymphocytic Leukemia Mikeska, Thomas
 2011
 11 S2 p. S159-
1 p.
 artikel
20 2.45 CCR4–Ligand Interactions Contribute Pro-Survival and Proliferative Signals to Chronic Lymphocytic Leukemia B Cells Damle, Rajendra N.
 2011
 11 S2 p. S188-
1 p.
 artikel
21 3.25 CD200 and CD148 Expression in B-Cell Non-Hodgkin's Lymphoma Fan, Lei
 2011
 11 S2 p. S213-S214
2 p.
 artikel
22 2.51 CD38, CD44 and β1 Integrins - CD49d, CD49c and CD29 in Different Microenvironment Have Different Pattern of Expression and Relationship to Survival Jaksic, Ozren
 2011
 11 S2 p. S192-
1 p.
 artikel
23 2.35 CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells Serra, Sara
 2011
 11 S2 p. S181-
1 p.
 artikel
24 2.34 CD38 is a Principal Component of the CLL ‘Invadosome’ Vaisitti, T.
 2011
 11 S2 p. S180-S181
2 p.
 artikel
25 2.1 CD84 is a Survival Receptor for CLL Cells Binsky-Ehrenreich, Inbal
 2011
 11 S2 p. S160-
1 p.
 artikel
26 3.26 Central Nervous System Infiltration in a Patient with Chronic Lymphocytic Leukemia Zawilska, Krystyna
 2011
 11 S2 p. S215-
1 p.
 artikel
27 4.33 Characteristics and Outcome of CLL Relapse Post-Fludarabine, Cyclophosphamide ± Rituximab Carney, Dennis A.
 2011
 11 S2 p. S241-S242
2 p.
 artikel
28 3.3 Characterization of Lymphadenopathy in Untreated Patients with Chronic Lymphocytic Leukemia Chellappa, Vivek
 2011
 11 S2 p. S197-S198
2 p.
 artikel
29 5.17 Chemoimmunotherapy Improves Survival of Patients with Chronic Lymphocytic Leukemia Ghita, Gabriela
 2011
 11 S2 p. S253-S255
3 p.
 artikel
30 5.33 Choosing Best Option for Patients > 65 years with Chronic Lymphocytic Leukemia: Balancing Disease Status and Comorbidities in an Unselected Community-Based Population Ysebaert, Loic
 2011
 11 S2 p. S265-S266
2 p.
 artikel
31 2.36 Chronic Lymphocytic Leukemia Associated with Autoimmune Hemolytic Anemia is Characterized by a Distinctive miRNA Signature Ferrer, Gerardo
 2011
 11 S2 p. S181-S182
2 p.
 artikel
32 5.55 Chronic Lymphocytic Leukemia Associated with Glomerular Disease: A Case Report of Successful Treatment with High-Dose Methyl-Prednisolone in combination with Rituximab Followed by Alemtuzumab Diaz-Perez, Julio A.
 2011
 11 S2 p. S282-S283
2 p.
 artikel
33 2.11 Chronic Lymphocytic Leukemia Cells Respond to CD180 Ligation by Alternative Signalling via Akt (PKB) or P38MAPK Pathways Porakishvili, Nino
 2011
 11 S2 p. S165-S167
3 p.
 artikel
34 5.60 Chronic Lymphocytic Leukemia: Contra-Indication for Transplantation? Dierickx, D.
 2011
 11 S2 p. S285-
1 p.
 artikel
35 2.18 Chronic Lymphocytic Leukemia: The Role of the PI3K Pathway in Microenvironment Interactions Lafarge, Sandrine T.
 2011
 11 S2 p. S171-
1 p.
 artikel
36 3.24 Chronic Myeloid Leukemia Developing in a Patient with B-Cell CLL – A Case Report Zawilska, Krystyna M.
 2011
 11 S2 p. S213-
1 p.
 artikel
37 2.29 Circulating CLL Cells Expressing Markers of Clinical Aggressiveness Display a Phosphoproteomic Profile Consistent with a Constitutive Receptor Engagement Benedetti, Dania
 2011
 11 S2 p. S177-S178
2 p.
 artikel
38 1.21 Clinical and Molecular-Pathological Characteristics of Richter's Syndrome Davis, Ian
 2011
 11 S2 p. S154-S155
2 p.
 artikel
39 2.41 Clinical Significance of Sex Chromosome Loss in Chronic Lymphocytic Leukemia Antony-Debré, I.
 2011
 11 S2 p. S184-S185
2 p.
 artikel
40 2.55 CLL Cell Survival Depends on B Cell Receptor Signaling-Induced NFAT2 Activation Le Roy, Christine
 2011
 11 S2 p. S194-S195
2 p.
 artikel
41 2.50 CLL Lymph Node T-Cells Show Evidence of Chronic Antigenic Stimulation and a Skewed T-Cell Receptor Repertoire Yallop, Deborah
 2011
 11 S2 p. S191-S192
2 p.
 artikel
42 1.27 Clonal Evolution with a Cryptic t(11;14) Janssens, Ann
 2011
 11 S2 p. S158-
1 p.
 artikel
43 2.26 Clopidogrel (Plavix) Induces In Vivo Reduction of Normal B Cells and In Vitro Apoptosis of B-Cell Chronic Lymphocytic Leukemia Cells Berrebi, Alain
 2011
 11 S2 p. S175-
1 p.
 artikel
44 5.10 Combination of Bendamustine and Ofatumumab (Bendofa) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Preliminary Report Cortelezzi, Agostino
 2011
 11 S2 p. S248-S249
2 p.
 artikel
45 5.2 Combinatory Effect of PARP Inhibition with Existing Low-Toxicity Chromatin Modifying Agents (HDAC Inhibitors) Sensitizes CLL Tumors with DNA Damage Response Defect Stankovic, T.
 2011
 11 S2 p. S243-S244
2 p.
 artikel
46 5.28 Combining Fludarabine and Rituximab With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia: The REVLIRIT CLL5 AGMT Phase 1/2 Study—Results from Clinical and Exploratory Analyses of Induction Egle, A.
 2011
 11 S2 p. S261-S262
2 p.
 artikel
47 1.22 Comparative Assessment of Two Kinase Inhibitors, Sorafenib and Dasatinib, on CLL Cells Kuckertz, Mirjam
 2011
 11 S2 p. S155-S156
2 p.
 artikel
48 4.32 Comparison between the International Standardised Approach and a Single Tube Ten Colour Flow Cytometric Assay for Detection of Minimal Residual Disease in CLL Sartor, M.
 2011
 11 S2 p. S240-S241
2 p.
 artikel
49 5.44 Consolidation Therapy with Subcutaneous Alemtuzumab after Induction Treatment with Oral Fludarabine and Cyclophosphamide in Previously Untreated Patients Aged 65-70 years with Advanced Stage CLL: Final Results of a Phase II Study from the French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia (FCG-CLL/WM) Delmer, Alain
 2011
 11 S2 p. S273-S275
3 p.
 artikel
50 2.2 Controlled Depletion of Autologous T Cells Facilitates a Lasting CLL Proliferation in the CLL Xenograft Model Skowronska, A.
 2011
 11 S2 p. S160-S161
2 p.
 artikel
51 2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth Evans, E.
 2011
 11 S2 p. S173-S174
2 p.
 artikel
52 5.50 CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Exhibits CLL Antitumor Activity Prins, Renee
 2011
 11 S2 p. S278-S279
2 p.
 artikel
53 2.8 CXCL12 Is a Costimulator for CD4+ T-Cell Activation and Proliferation in Patients with Chronic Lymphocytic Leukemia Borge, Mercedes
 2011
 11 S2 p. S164-
1 p.
 artikel
54 4.6 Detection and Analysis of TP53 and ATM Deletions by Multiplex Ligation-Dependent Probe Amplification in CLL Robinson, Hazel M.
 2011
 11 S2 p. S221-
1 p.
 artikel
55 4.9 Detection of p53 Dysfunction in Chronic Lymphocytic Leukemia by an In Vitro Functional Assay Based on p53 Activation by the Nongenotoxic Drug Nutlin-3 Pozzo, Federico
 2011
 11 S2 p. S222-S223
2 p.
 artikel
56 1.29 Development of Highly Accurate RT-qPCR Assays for Profiling the Expression of DNA Repair and Apoptosis Genes in CLL Mikeska, Thomas
 2011
 11 S2 p. S158-S159
2 p.
 artikel
57 2.27 Differential Gene Expression and Secretory Profiles of Nurse-like Cells Specifically Derived from Chronic Lymphocytic Leukemia Help Decipher New Pathways to Pathogenesis Ysebaert, Loic
 2011
 11 S2 p. S175-S176
2 p.
 artikel
58 3.19 Disease Characteristics and Response to First Therapy in African American Patients with CLL: the M.D. Anderson Cancer Center Experience Falchi, Lorenzo
 2011
 11 S2 p. S209-S210
2 p.
 artikel
59 3.22 Diversity of T-Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia Holler, C.
 2011
 11 S2 p. S212-
1 p.
 artikel
60 1.14 DNA Methylation Status is Associated to Lipoprotein Lipase (LPL) Expression and can be Modulated by FC Treatment in Unmutated CLL Patients Abreu, C.
 2011
 11 S2 p. S149-S150
2 p.
 artikel
61 1.18 Double/Triple Productive Immunoglobulin Rearrangements in Chronic Lymphocytic Leukemia Patients Plevova, Karla
 2011
 11 S2 p. S152-S153
2 p.
 artikel
62 Editorial Board/Masthead 2011
 11 S2 p. A3-
1 p.
 artikel
63 2.10 Effect of Sequential Ligation of CD180/RP105 and sIgM on Downstream Signalling in CLL Cells Vispute, Ketki
 2011
 11 S2 p. S165-S166
2 p.
 artikel
64 5.36 Effect of Valproic Acid on Fludarabine Activity in Chronic Lymphocytic Leukemia Yoon, J.
 2011
 11 S2 p. S268-
1 p.
 artikel
65 5.34 Efficacy of FC and FCR Regimens in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: 9 Years of Follow-up Stadnik, E.
 2011
 11 S2 p. S266-S267
2 p.
 artikel
66 3.5 Elevated Levels of Both Membrane-Bound and Soluble Forms of a Receptor Specific for the Fragment Crystallizable Region of Immunoglobulin M in Patients with CLL Li, Fu Jun
 2011
 11 S2 p. S199-
1 p.
 artikel
67 4.1 Elevated Serum Free Light Chains Independently Identify a Poor Risk Group of Stage A CLL Patients Pratt, Guy
 2011
 11 S2 p. S218-
1 p.
 artikel
68 3.8 Epidemiology of CLL in Basse-Normandie (France) Troussard, Xavier
 2011
 11 S2 p. S200-S201
2 p.
 artikel
69 3.2 Evolution of High-Sensitivity, Multi-Color Flow Cytometric Immunophenotyping for Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia: Peripheral Blood versus Bone Marrow? Hanson, C.A.
 2011
 11 S2 p. S197-
1 p.
 artikel
70 4.22 Exploring the Clinical Significance of a Positive Direct Antiglobulin Test in CLL: A Community Hospital Experience Spyrou, A.
 2011
 11 S2 p. S233-
1 p.
 artikel
71 2.13 Expression and Function of the NF-κB Subunits in Chronic Lymphocytic Leukemia: A Role for DNA-Dependent Protein Kinase in Regulating DNA Damage–Activated p65 and p50 Subunit Activation Mulligan, E.A.
 2011
 11 S2 p. S167-S168
2 p.
 artikel
72 4.5 Expression of the BAG3 Gene in Chronic Lymphocytic Leukemia and Its Clinical Significance Zhu, Huayuan
 2011
 11 S2 p. S220-
1 p.
 artikel
73 2.4 Expression of TLRs in B-CLL: Relationship with Disease Activity Barcellini, Wilma
 2011
 11 S2 p. S161-S162
2 p.
 artikel
74 2.22 Expression Profile and Regulation of BAFF and APRIL Receptors in Chronic Lymphocytic Leukemia Ferrer, Gerardo
 2011
 11 S2 p. S172-S173
2 p.
 artikel
75 5.31 Factors Associated with Complete Response and Treatment Failure in Primary CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab: First Interim Analysis of MLSG08_1 Trial Nikitin, E.
 2011
 11 S2 p. S264-
1 p.
 artikel
76 3.9 Familial CLL in Norway Jønsson, Viggo
 2011
 11 S2 p. S201-
1 p.
 artikel
77 4.29 FCRL2 is a Distinct Marker of MT-CLL that Predicts Both Clinical Progression and Survival Li, Fu Jun
 2011
 11 S2 p. S239-
1 p.
 artikel
78 5.39 Feasibility Analysis of Non-myeloablative Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia and 17p Deletion Hsu, Yvonne
 2011
 11 S2 p. S270-
1 p.
 artikel
79 4.15 FISH for CLL – A More Sensitive Scoring Method Smoley, Stephanie A.
 2011
 11 S2 p. S227-S228
2 p.
 artikel
80 4.28 FISH on Paraffin-Embedded Tissue Samples is Feasible and of Prognostic Importance in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Norin, Stefan
 2011
 11 S2 p. S238-
1 p.
 artikel
81 5.8 Fludarabine-Cyclophosphamide-Rituximab vs Autologous Stem Cell Transplantation as First-Line Treatment for CLL: A Comparison of 2 Prospective Studies of the GCLLSG Dreger, P.
 2011
 11 S2 p. S247-
1 p.
 artikel
82 2.19 Fludarabine-Induced Changes in p63 and p73 Expression and TP53 Protein Binding in TP53 Wild-Type and Mutated Cell Lines Al-Mazi, Juhura G.
 2011
 11 S2 p. S171-
1 p.
 artikel
83 2.49 Follow-Up Study on the Association of Merkel Cell Polyomavirus and CLL/SLL Confirms Viral Presence and Integration by Fluorescence In Situ Hybridization Hausen, Axel zur
 2011
 11 S2 p. S190-S191
2 p.
 artikel
84 4.21 Functional Categorisation of Tumour Cell p53/p21 Responses to Etoposide and Nutlin3a Exposure Correlates with Bi-allelic ATM Lesions and Mono- or Bi-allelic Lesions of TP53 in Chronic Lymphocytic Leukaemia Tracy, Ian
 2011
 11 S2 p. S231-S233
3 p.
 artikel
85 1.16 Gene Set Enrichment Analysis of CLL Subgroups Defined by Ki-67 Expression Yan, Xiao-Jie
 2011
 11 S2 p. S151-S152
2 p.
 artikel
86 1.13 Genome Fingerprinting of a Proliferative B-cell Subset in Chronic Lymphocytic Leukemia Oppezzo, P.
 2011
 11 S2 p. S149-
1 p.
 artikel
87 1.5 Genomic Heterogeneity in Chronic Lymphocytic Leukemia Friedman, Daphne R.
 2011
 11 S2 p. S143-S144
2 p.
 artikel
88 4.27 Genomic Variability Predicts Time-to-Treatment in Previously Untreated CLL Patients Schweighofer, Carmen D.
 2011
 11 S2 p. S237-S238
2 p.
 artikel
89 2.53 HDAC-Mediated Silencing of miR-17 and miR-20a in Chronic Lymphocytic Leukemia Sulda, Melanie
 2011
 11 S2 p. S193-S194
2 p.
 artikel
90 4.11 High-Throughput VDJ Sequencing for Chronic Lymphocytic Leukemia: Minimal Residual Disease Quantification and Immunoglobulin Repertoire Assessment Following Hematopoietic Cell Transplantation Logan, Aaron C.
 2011
 11 S2 p. S224-
1 p.
 artikel
91 5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic Reticulum Chaperone Proteins Che, Yiping
 2011
 11 S2 p. S260-S261
2 p.
 artikel
92 2.3 HS1 Protein Defines a Distinct Signaling Pathway and Influences the Cell Homing and Migratory Capacity in CLL Primary Cells Scielzo, Cristina
 2011
 11 S2 p. S161-
1 p.
 artikel
93 2.48 Identification and Validation of Potential Targets for the Diagnosis and Therapy of CLL Varghese, Abraham M.
 2011
 11 S2 p. S189-S190
2 p.
 artikel
94 2.28 Identification by Serological Proteome Analysis (SERPA) of Novel Tumor Associated Antigens in Chronic Lymphocytic Leukemia (CLL) Coscia, M.
 2011
 11 S2 p. S176-S177
2 p.
 artikel
95 2.52 Identification of BST2 as a Potential Therapeutic Target in B Cell Malignancies Including Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Burke, Russell
 2011
 11 S2 p. S192-S193
2 p.
 artikel
96 4.16 Identification of Minor Proportion p53 Mutations Selected Later by Therapy Malcikova, Jitka
 2011
 11 S2 p. S228-
1 p.
 artikel
97 4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia Huang, Pauline Y.
 2011
 11 S2 p. S221-S222
2 p.
 artikel
98 1.25 Impact of Bone Marrow Microenvironment on 93 Apoptotic Pathway Target mRNA Expression in CLL Cells Patel, Viralkumar
 2011
 11 S2 p. S157-
1 p.
 artikel
99 3.16 Increased Incidence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Patients with Merkel Cell Carcinoma in Israel Tadmor, Tamar
 2011
 11 S2 p. S206-S207
2 p.
 artikel
100 3.13 Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Community-based Cohort Study of Newly Diagnosed Patients Compared to Controls Moreira, Jonathan
 2011
 11 S2 p. S204-S205
2 p.
 artikel
101 1.1 Inhibition of Deubiquitinating Enzyme USP7 Sensitizes CLL Tumor with ATM and p53 Dysfunction by Targeting Both Mdm2/p53 Loop and DNA Repair Agathanggelou, A.
 2011
 11 S2 p. S141-
1 p.
 artikel
102 5.20 Inhibition of DNA-Dependent Protein Kinase Chemosensitises ATM Mutant Chronic Lymphocytic Leukaemia Cells Willmore, E.
 2011
 11 S2 p. S256-S257
2 p.
 artikel
103 1.11 Integrative Genomic Analysis Implicates PIK3CA and MYC in Chronic Lymphocytic Leukemia Brown, Jennifer R.
 2011
 11 S2 p. S147-S148
2 p.
 artikel
104 5.38 Interest of Early Determination of Bone Marrow Minimal Residual Disease by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: the Experience of the CLL2007FMP, an Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine, Cyclophosphamide, and Rituximab versus Fludarabine, Cyclophosphamide, and MabCampath in Previously Untreated B-Chronic Lymphocytic Leukemia Patients Letestu, Remi
 2011
 11 S2 p. S269-
1 p.
 artikel
105 2.7 Intra-Clonal Diversity Identified by CD19-Mediated Signaling Correlates with Disease Progression in CLL Herishanu, Yair
 2011
 11 S2 p. S163-
1 p.
 artikel
106 1.31 Investigating Methylation of the Pro-Apoptotic CLL Tumour Suppressor Gene, Death Associated Protein Kinase 1 (DAPK1) Candiloro, Ida
 2011
 11 S2 p. S159-
1 p.
 artikel
107 4.8 Investigation of Notch1 Mutation in Chinese Patients with B-Cell Chronic Lymphocytic Leukemia Shen, Wenyi
 2011
 11 S2 p. S222-
1 p.
 artikel
108 5.51 Is Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) in CLL Still Under Debate? A Population Matched Analysis Between Auto-HSCT and Rituximab-Fludarabine-Cyclophosphamide in First-Line CLL Patients Michallet, Anne-Sophie
 2011
 11 S2 p. S279-S280
2 p.
 artikel
109 2.5 Lck is an Important Mediator of BCR-induced Signaling in CLL Cells Talab, Fatima
 2011
 11 S2 p. S162-
1 p.
 artikel
110 5.11 Lenalidomide Consolidation Seems to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated Chronic Lymphocytic Leukemia Shanafelt, T.
 2011
 11 S2 p. S249-
1 p.
 artikel
111 5.59 Lenalidomide Induces Long-lasting Responses in Elderly Patients with Chronic Lymphocytic Leukemia Pemmaraju, N.
 2011
 11 S2 p. S284-S285
2 p.
 artikel
112 5.22 Long-Term Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukaemia: A Single-Centre Experience Krawczyk-Kuliś, Małgorzata
 2011
 11 S2 p. S257-S258
2 p.
 artikel
113 5.32 Long-term Outcome of B-CLL Patients Treated in a Prospective Trial Evaluating Combination of Oral Fludarabine and Cyclophosphamide as Frontline Therapy Guièze, Romain
 2011
 11 S2 p. S264-S265
2 p.
 artikel
114 1.28 Low CD20 Expression in Chronic Lymphocytic Leukemia is not Associated with CD20 Gene Mutation Fang, Cheng
 2011
 11 S2 p. S158-
1 p.
 artikel
115 5.27 Low-Dose Fludarabine and Cyclophosphamide Combined With Rituximab Is a Safe and Effective Treatment Option for Elderly and Comorbid Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Preliminary Results of Project Q-lite, by the Czech CLL Study Group Smolej, Lukáš
 2011
 11 S2 p. S261-
1 p.
 artikel
116 4.20 MatBA™: A Targeted Oligonucleotide Array for the Assessment of Genomic Copy Number Alterations for Risk Stratification in Chronic Lymphocytic Leukemia Houldsworth, Jane
 2011
 11 S2 p. S231-S232
2 p.
 artikel
117 4.23 MDM2 Promotor Polymorphism and Disease Characteristics in CLL: Individual Patient Data Meta-Analysis of 2598 CLL Patients Benner, Axel
 2011
 11 S2 p. S233-S235
3 p.
 artikel
118 2.43 Mesenchymal Progenitors from Chronic Lymphocytic Leukemia Bone Marrow Aspirates are Rare and Display an Altered Phenotype Dubois-Galopin, Frédérique
 2011
 11 S2 p. S186-S187
2 p.
 artikel
119 1.8 MicroRNA Mutational Analysis in Patients with Chronic Lymphocytic Leukemia Lochmanova, J.
 2011
 11 S2 p. S145-S146
2 p.
 artikel
120 5.18 Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase 1–2 Study and Future Plans Haran, Michal
 2011
 11 S2 p. S255-
1 p.
 artikel
121 2.42 Mimicking the Tumor Microenvironment: Three Different Co-culture Systems Induce a Similar Phenotype but Different Proliferative Signals in Primary Chronic Lymphocytic Leukemia Cells Hamilton, Emma
 2011
 11 S2 p. S185-S186
2 p.
 artikel
122 1.4 MiR-181a/b Significantly Enhance Drug Sensitivity of CLL Cells via Targeting Multiple Anti-Apoptosis Genes Zhu, Dan-Xia
 2011
 11 S2 p. S143-
1 p.
 artikel
123 2.33 Modulation of Autophagy by the UPR Results in Apoptosis in CLL Cells Wickremasinghe, R. Gitendra
 2011
 11 S2 p. S180-
1 p.
 artikel
124 4.12 Monitoring Minimal Residual Disease Post-FCR in Patients with Chronic Lymphocytic Leukemia Predicts Survival: Implications for Preemptive Treatment of Relapse Ysebaert, Loic
 2011
 11 S2 p. S224-S226
3 p.
 artikel
125 4.26 Monoallelic versus Biallelic 139 Deletion in B-CLL May Confer a Poorer Prognosis Sinhal, Smita
 2011
 11 S2 p. S236-S237
2 p.
 artikel
126 5.37 Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Fludarabine plus Cyclophosphamide plus Rituximab in Patients with CLL Maloum, K.
 2011
 11 S2 p. S268-S269
2 p.
 artikel
127 3.1 Natural History of Splenomegaly in CLL from Automated Volumetric Analysis Linguraru, Marius G.
 2011
 11 S2 p. S196-
1 p.
 artikel
128 5.46 NCRN CLL207 Study of Alemtuzumab Consolidation in Chronic Lymphocytic Leukaemia: Response Assessment Follow-up and Pharmacokinetic studies (on Behalf of the NCRI CLL Trials Sub-Group) Varghese, Abraham M.
 2011
 11 S2 p. S275-S276
2 p.
 artikel
129 2.44 Observations Using Video-Microscopy and Cytofluorescence Highlight Dynamic Cytoskeleton-driven Homotypic and Heterotypic Interactions of Chronic Lymphocytic Leukaemia Cells – New Understandings and Opportunities for Therapy Hutchinson, Claire V.
 2011
 11 S2 p. S187-
1 p.
 artikel
130 5.6 Ofatumumab and Bendamustine in Previously Treated CLL and SLL Ujjani, Chaitra S.
 2011
 11 S2 p. S245-S246
2 p.
 artikel
131 5.12 Ofatumumab-Based Chemoimmunotherapy for Patients With Previously Untreated Chronic Lymphocytic Leukemia Shanafelt, T.
 2011
 11 S2 p. S250-
1 p.
 artikel
132 5.56 Ofatumumab in Combination with High-Dose Methylprednisolone as a Salvage Treatment for Heavily Pretreated or Refractory Patients with Chronic Lymphocytic Leukemia Barajas-Gamboa, Juan S.
 2011
 11 S2 p. S283-
1 p.
 artikel
133 2.16 Overexpression of the Autoimmunity-Associated Tyrosine Phosphatase PTPN22 in CLL Cells Enhances Antiapoptotic B-Cell Receptor Signals Through Selective Activation of the AKT Pathway Negro, Roberto
 2011
 11 S2 p. S169-S170
2 p.
 artikel
134 2.40 Paradoxical Effects of Fc Gamma Receptor IIb Engagement on the Modulation of BCR Signaling in Chronic Lymphocytic Leukemia B Cells Moreno, Carol
 2011
 11 S2 p. S184-
1 p.
 artikel
135 5.57 Pattern of Use and Effectiveness of Rituximab-Based Therapy in CLL/SLL in the Province of Manitoba, Prior to its Approval as First-Line Treatment for CLL Guilbert, Kimi
 2011
 11 S2 p. S283-S284
2 p.
 artikel
136 5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B) Brown, Jennifer R.
 2011
 11 S2 p. S272-S274
3 p.
 artikel
137 5.24 Pentostatin, Alemtuzumab, and Low-Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Zent, Clive S.
 2011
 11 S2 p. S258-S259
2 p.
 artikel
138 5.4 Phase-I-II Study of the Combination of Lenalidomide and Alemtuzumab in Patients with Advanced-Stage CLL Lundin, Jeanette
 2011
 11 S2 p. S244-S245
2 p.
 artikel
139 5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results Seymour, John F.
 2011
 11 S2 p. S258-
1 p.
 artikel
140 2.47 p53 Homolog p63 Promotes Apoptosis and Chemosensitivity in Chronic Lymphocytic Leukemia B-Cells Collins, Ryan
 2011
 11 S2 p. S189-
1 p.
 artikel
141 2.31 Phosphoinositide 3'-Kinase (PI3K) Delta Inhibition with CAL-101 (GS 1101) Significantly Alters Chemokines and Shows Increased In Vitro Activity in Unmutated IgVh CLL Compared to Mutated IgVh Samples Spurgeon, Stephen E.
 2011
 11 S2 p. S178-S179
2 p.
 artikel
142 3.11 Population-Based Analysis of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia (CLL): Provincial Laboratory Standardization and Prevalence of FISH Abnormalities in British Columbia (BC), Canada Gerrie, Alina S.
 2011
 11 S2 p. S202-S203
2 p.
 artikel
143 5.29 Potential of AFX-2, a Unique, Polysaccharide-Based Toll-like Receptor Agonist, in Patients With Chronic Lymphocytic Leukemia Sagar, Stephen M.
 2011
 11 S2 p. S262-S263
2 p.
 artikel
144 4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group Fink, Anna
 2011
 11 S2 p. S230-
1 p.
 artikel
145 5.30 Preliminary Results from a Phase I/II Study of Fludarabine (F), Rituximab (R), and Lenalidomide (L) in Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Flinn, Ian W.
 2011
 11 S2 p. S263-S264
2 p.
 artikel
146 3.30 Prevalence and Characteristics of AIHA/ITP in CLL/SLL in Manitoba: Need for Consensus Criteria Lakhi, Sunjay
 2011
 11 S2 p. S216-S217
2 p.
 artikel
147 3.15 Prevalence of MBL Increases over Time in Relatives of CLL Families Slager, Susan L.
 2011
 11 S2 p. S206-
1 p.
 artikel
148 4.31 Prognostic Significance of CD20 in Chinese Patients with Chronic Lymphocytic Leukemia Fang, Cheng
 2011
 11 S2 p. S240-
1 p.
 artikel
149 4.3 Prognostic Significance of Dicer and Drosha Expression in Patients with CLL Zhu, Dan-Xia
 2011
 11 S2 p. S219-
1 p.
 artikel
150 4.13 Proposal of a New Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on an Overall Survival Analysis of Three German CLL Study Group Phase III Trials Bahlo, Jasmin
 2011
 11 S2 p. S225-S227
3 p.
 artikel
151 2.9 Pro-Survival Signalling in ‘Responder' CLL Cells After Ligation of CD180 Porakishvili, Nino
 2011
 11 S2 p. S164-S165
2 p.
 artikel
152 2.12 Provision of Human Multimeric sCD40L and Interleukin-4 to Immune-Deficient NOD/SCID/γc null Mice Permits Efficient and Effective Adoptive Transfer and T-Cell–Independent Proliferation of CLL Cells In Vivo Simone, Rita
 2011
 11 S2 p. S166-S167
2 p.
 artikel
153 5.16 Pulse-Dosed Lenalidomide in Relapsed/Refractory Chronic Lymphocytic Leukemia: Immune Activation Correlates with Favorable Responses Aue, Georg
 2011
 11 S2 p. S252-S253
2 p.
 artikel
154 5.3 R-DHAP Immuno-Chemotherapy is an Effective Remission-Induction Treatment for Fludarabine-Refractory Patients or Those with del17p Before Allogeneic Stem Cell Transplantation; Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial van Gelder, M.
 2011
 11 S2 p. S244-
1 p.
 artikel
155 5.49 Real-Life First-Line Treatment of B-CLL – A Population-Based Prospective Study Following NICE Guidelines Permitting Use of Fludarabine, Cyclophosphamide and Rituximab – A Preliminary Report Todd, Dr Anthony
 2011
 11 S2 p. S277-S278
2 p.
 artikel
156 1.2 Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of CLL Maura, Francesco
 2011
 11 S2 p. S141-S142
2 p.
 artikel
157 5.15 Resistance to Complement-Dependent Cytotoxicity in Chronic Lymphocytic Leukemia Cells from Patients Treated with Ofatumumab Baig, Nisar A.
 2011
 11 S2 p. S251-S252
2 p.
 artikel
158 3.10 Risk Factors Associated with Chronic Lymphocytic Leukaemia in a Spanish Case−Control Study (MCC−Spain) Benavente, Y.
 2011
 11 S2 p. S202-
1 p.
 artikel
159 4.2 Risk Factors of CLL Transformation to Richter's Syndrome Xu, Wei
 2011
 11 S2 p. S218-S219
2 p.
 artikel
160 5.14 Rituximab in Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia with Fludarabine Plus Total Body Irradiation Conditioning: Results of a Phase 2 Prospective Multicenter Study (ITAC 02-02) Michallet, Mauricette
 2011
 11 S2 p. S250-S251
2 p.
 artikel
161 5.45 Rituximab Infusion-Related Toxicity In Patients With CLL Simkovic, M.
 2011
 11 S2 p. S275-
1 p.
 artikel
162 5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC) Bosch, Francesc
 2011
 11 S2 p. S270-S272
3 p.
 artikel
163 5.21 ROR1-Immunotoxin as a Potential Therapeutic Agent for Certain Human B-cell Malignancies Baskar, Sivasubramanian
 2011
 11 S2 p. S257-
1 p.
 artikel
164 5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study Mulligan, Stephen P.
 2011
 11 S2 p. S259-S260
2 p.
 artikel
165 1.17 Search for an Etiological Virus Candidate in Chronic Lymphocytic Leukemia by Extensive Transcriptome Analysis Rego, N.
 2011
 11 S2 p. S152-
1 p.
 artikel
166 2.24 Sensitization of High-Risk Chronic Lymphocytic Leukemia Cells to Fludarabine Using Inhibition of DNA-Dependent Protein Kinase Sebejova, Ludmila
 2011
 11 S2 p. S174-
1 p.
 artikel
167 1.19 Sequential Genomic Analysis of Untreated Patients with Chronic Lymphocytic Leukemia Demonstrates Clonal Evolution Put, Natalie
 2011
 11 S2 p. S153-S154
2 p.
 artikel
168 2.46 Signal Transducer and Activator of Transcription 3 and Nuclear Factor κB Activation Regulate Autocrine Interleukin-6 Production and Indicate the Prognosis of CLL Liu, Fengting
 2011
 11 S2 p. S188-S189
2 p.
 artikel
169 3.17 Similar Rates of Invasive Fungal Disease in CLL and ‘High-Risk' Acute Myeloid Leukaemia/Allogeneic Transplant Patients Araf, Shamzah
 2011
 11 S2 p. S207-S208
2 p.
 artikel
170 1.20 Some Features of Gene Repertoire of IGHV/D/J Rearrangements in Chronic Lymphocytic Leukemia Patients Exposed to Ionizing Radiation due to the Chernobyl Nuclear Power Plant Accident Bilous, N.
 2011
 11 S2 p. S154-
1 p.
 artikel
171 3.7 Spectral Karyotype Analysis (SKY) in Chronic Lymphocytic Leukemia: Correlation Between Immunostimulated Classical Cytogenetics and FISH Morato, Fábio
 2011
 11 S2 p. S200-
1 p.
 artikel
172 3.20 Stereotyped B-Cell Receptor is Associated with Immune Thrombocytopenia in CLL Maura, Francesco
 2011
 11 S2 p. S209-
1 p.
 artikel
173 1.10 Stereotyped B-Cell Receptors in Patients with Chronic Lymphocytic Leukemia in China Qiao, Chun
 2011
 11 S2 p. S147-
1 p.
 artikel
174 Table of Contents 2011
 11 S2 p. A4-
1 p.
 artikel
175 3.23 Targeted Nanoparticle Delivery Overcomes Off-Target Immunostimulatory Effects of Oligonucleotides and Improves Therapeutic Efficacy Muthusamy, Natarajan
 2011
 11 S2 p. S213-
1 p.
 artikel
176 2.54 Targeting Refractory CLL Lacking ATM Function with Sapacitabine-Containing Therapy Jiang, Yingjun
 2011
 11 S2 p. S194-
1 p.
 artikel
177 4.24 Telomere Dysfunction is the Critical Determinant of Clinical Outcome in CLL Lin, Thet Thet
 2011
 11 S2 p. S234-S235
2 p.
 artikel
178 1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia Palma, Marzia
 2011
 11 S2 p. S145-
1 p.
 artikel
179 1.24 Telomere Shortening in CLL Correlates with Cell Cycle-Dependent Dysregulation of Shelterin Proteins Ishdorj, G.
 2011
 11 S2 p. S156-
1 p.
 artikel
180 3.21 Th17 and non-Th17 IL-17-Expressing Cells in CLL: Delineation, Distribution, and Clinical Relevance Jain, Preetesh
 2011
 11 S2 p. S211-S212
2 p.
 artikel
181 5.53 The Anti-Tumor Reactivity of ROR1-CAR Modified T Cells Depends on the Targeted Epitope, CAR-Affinity and Design of the CAR Extracellular Domain Hudecek, Michael
 2011
 11 S2 p. S280-S281
2 p.
 artikel
182 2.20 The Biological Role of BAG3 in Human Chronic Lymphatic Leukemia Zhu, Huayuan
 2011
 11 S2 p. S172-
1 p.
 artikel
183 4.18 The Clinical Significant of NOTCH1 and MYD88 Mutations in Patients Enrolled onto the UK CLL4 Treatment Trial and in an Early Stage A CLL Cohort Rose-Zerilli, M.J.
 2011
 11 S2 p. S229-
1 p.
 artikel
184 3.29 The CLL Literature is Continuing to Grow But We Need to Enter More Patients into Randomised Controlled Trials (RCTs) to Improve Our Evidence Base Copplestone, Adrian
 2011
 11 S2 p. S216-
1 p.
 artikel
185 1.23 The Cytokine Midkine and its Receptor Tyrosine Phosphatase Zeta Regulate B Cell Survival in Health and Disease in a Pathway Induced by CD74 Cohen, Sivan
 2011
 11 S2 p. S156-
1 p.
 artikel
186 5.52 The DNA-Strand-Breaking Nucleoside Analog Sapacitabine: Mechanism-Based Drug Combinations Liu, Xiaojun
 2011
 11 S2 p. S280-
1 p.
 artikel
187 1.15 The Genome-Wide Analysis of Copy Number Alterations and Acquired UPD Events in CLL Strefford, J.C.
 2011
 11 S2 p. S150-S151
2 p.
 artikel
188 5.42 The Heat Shock Protein 90 Inhibitor AUY922 is Effective in Combination with Fludarabine Against CLL Cells Cultured on a CD40L-Stromal Layer and Inhibits Their Activated/Proliferative Phenotype Best, Giles
 2011
 11 S2 p. S272-
1 p.
 artikel
189 5.7 The Impact of Specific Mutations in TP53 Gene on the Results of Alemtuzumab Therapy in CLL Patients Doubek, Michael
 2011
 11 S2 p. S246-S247
2 p.
 artikel
190 3.14 The Influence of Genetic Background and Infectious Exposure on the Development of Chronic Lymphocytic Leukaemia and Other B-Cell Malignancies: Evidence from High-Sensitivity Screening in Leeds and Rural Uganda Ssemaganda, Aloysius
 2011
 11 S2 p. S205-S206
2 p.
 artikel
191 4.30 The Intellectual History of Chronic Lymphocytic Leukemia: iwCLL 1979–2011 Marti, Gerald
 2011
 11 S2 p. S239-S240
2 p.
 artikel
192 2.15 The Irf4 Gene, a Susceptibility Locus for Chronic Lymphocytic Leukemia, Controls Establishment of Follicular and Marginal Zone B-Cell Compartments in Mice Simonetti, Giorgia
 2011
 11 S2 p. S168-S169
2 p.
 artikel
193 2.14 The Kinetics of Phosphorylation of the CD5 Regulatory Domain in Chronic Lymphocytic Leukemia B Cells Reflects Ongoing Activation of the B-Cell Receptor Gary-Gouy, Hélène
 2011
 11 S2 p. S168-
1 p.
 artikel
194 3.18 The Manitoba Population Based Study of Chronic Lymphocytic Leukemia: Incidence of Second Malignancies Beiggi, Sara
 2011
 11 S2 p. S208-S209
2 p.
 artikel
195 2.38 The Microtubules Inhibitor Nocodazole is Highly Selective in Killing B Cells from Chronic Lymphocytic Leukemia by Targeting Kinase Lyn Frezzato, F.
 2011
 11 S2 p. S182-S183
2 p.
 artikel
196 1.3 The mRNA Expression Level of Puma, Noxa and Bim in CLL Cells Induced by Fludarabine In Vitro Xu, Wei
 2011
 11 S2 p. S142-S143
2 p.
 artikel
197 5.41 The Possible Origins of Myelodysplastic Changes Which Appear After Immunotherapy for CLL Braester, A.
 2011
 11 S2 p. S271-S272
2 p.
 artikel
198 4.10 The p53 Pro72 Allele Potentially Increases the Poor Prognostic Significance of p53 Mutation in Chronic Lymphocytic Leukemia Dong, Hua-Jie
 2011
 11 S2 p. S223-S224
2 p.
 artikel
199 3.12 The Prevalence of Serious Infections in a Community-Based Cohort of Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study Moreira, Jonathan
 2011
 11 S2 p. S203-S204
2 p.
 artikel
200 2.32 The p90RSK Inhibitor BI-D1870 Induces Apoptosis in CLL Cells Steele, Andrew
 2011
 11 S2 p. S179-
1 p.
 artikel
201 5.1 Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in CLL Yang, Jiahui
 2011
 11 S2 p. S243-
1 p.
 artikel
202 3.6 The Role of Imaging Methods in CLL: Significant Internal Lymphadenopathy is Frequent and Associated with Shorter Overall Survival Bachh, Aadil
 2011
 11 S2 p. S199-S200
2 p.
 artikel
203 1.9 The Significance of Deletion Architecture, ATM Mutational Status and Genomic Complexity in 11q Deleted CLL Rose-Zerilli, M.J.J.
 2011
 11 S2 p. S146-S147
2 p.
 artikel
204 2.30 Transcriptional Inhibition: Mechanism of Action for CDK Inhibitors in CLL to Overcome Microenvironment-Mediated Protection Chen, Rong
 2011
 11 S2 p. S178-
1 p.
 artikel
205 1.12 Transcriptome Sequencing Reveals Novel Mutations and Differential Gene Expression in Stereotyped Subsets of Chronic Lymphocytic Leukemia Sutton, Lesley-Ann
 2011
 11 S2 p. S148-S149
2 p.
 artikel
206 3.28 Trompe L'Oeil Not Only in Painting: CLL Concomitant with Hairy Cell Leukemia is Not Rare Akrya, L.
 2011
 11 S2 p. S216-
1 p.
 artikel
207 5.47 Tyrosine Kinase Inhibitor, Gefitinib, is Cytotoxic Against Zeta-Chain-Associated Protein Kinase 70-Positive but not Zeta-Chain-Associated Protein Kinase 70-Negative CLL Cells Xiao, Wenyan
 2011
 11 S2 p. S276-
1 p.
 artikel
208 4.25 Update on the International Standardized Approach for Flow Cytometric Residual Disease Monitoring in CLL Rawstron, A.C.
 2011
 11 S2 p. S235-S236
2 p.
 artikel
209 3.27 Usefulness of Conventional Cytogenetic Testing in a Reference Laboratory in the Diagnosis/Prognosis of Patients with B Chronic Lymproliferative Disorders (B-CLD) of the Brazilian National Health System Morais, K.M.
 2011
 11 S2 p. S215-
1 p.
 artikel
210 1.26 Wnt/PCP Pathway Regulates B-Cell Migration in Chronic Lymphocytic Leukemia Kaucka, Marketa
 2011
 11 S2 p. S157-S158
2 p.
 artikel
                             210 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland